Status:
COMPLETED
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
50-99 years
Phase:
PHASE3
Brief Summary
This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and...
Eligibility Criteria
Inclusion
- Adults
- Impaired glucose tolerance
- Age dependent risk factors
Exclusion
- Frank diabetes
- For detailed information, call contact person.
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
9306 Patients enrolled
Trial Details
Trial ID
NCT00097786
Start Date
January 1 2002
End Date
October 1 2009
Last Update
November 8 2023
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, New Jersey, United States
2
Investigative Site, Argentina
3
Investigative Site, Australia
4
Multiple Locations, Austria